Clinical Trial

Psychiatric Nurse-Delivered Eye Movement Desensitization and Reprocessing (EMDR) for Adults With Post-Traumatic Stress Symptoms in Jordan

Study acronym: Experimental
Completed
View on ClinicalTrials.gov →
Summary
Here is a plain-language, registry-appropriate Brief Summary you can paste into the form. It is written for patients, families, and healthcare providers: Brief Summary This study examines whether Eye Movement Desensitization and Reprocessing (EMDR) therapy can reduce the severity of symptoms in adults experiencing post-traumatic stress disorder (PTSD) in Jordan. PTSD can develop after exposure to distressing or traumatic life events and may cause symptoms such as intrusive memories, avoidance, sleep problems, anxiety, and emotional distress. A total of 70 adult participants with moderate to severe PTSD symptoms were enrolled. Participants were assigned to one of two groups: an EMDR therapy group or a waitlist control group. Individuals in the EMDR group received structured therapy sessions delivered by a trained mental-health professional, while those in the waitlist group did not receive therapy during the study period but were offered treatment after the study ended. PTSD symptom severity was measured before treatment, immediately after the therapy sessions, and again one month later. The goal of the study was to determine whether EMDR therapy leads to meaningful and lasting reductions in PTSD symptoms compared with no immediate treatment. The findings of this research are intended to help healthcare providers and policymakers understand the value of EMDR as a non-pharmacological, evidence-based treatment option for individuals experiencing trauma-related distress, and to support improvements in mental-health services and trauma-informed care in Jordan.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-14.
Trial Details
NCT Number NCT07423832
Lead Sponsor Al-Quds University
Conditions PTSD - Post Traumatic Stress Disorder
Enrollment 70 participants
Start Date 2023-03-15
Primary Completion 2023-12-25 (estimated)
Study Completion 2024-02-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-03